Journal article
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy
Abstract
PurposeAddition of rolapitant to standard antiemetic therapy improved protection against chemotherapy-induced nausea and vomiting (CINV) in phase 3 trials of patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). Here, we assessed the impact of CINV on the daily lives of patients receiving HEC or MEC using the Functional Living Index-Emesis (FLIE).MethodsIn three double-blind phase 3 studies, …
Authors
Chasen M; Urban L; Schnadig I; Rapoport B; Powers D; Arora S; Navari R; Schwartzberg L; Gridelli C
Journal
Supportive Care in Cancer, Vol. 25, No. 1, pp. 85–92
Publisher
Springer Nature
Publication Date
January 2017
DOI
10.1007/s00520-016-3388-7
ISSN
0941-4355